GlassScriptPhysician profile
Katerina Warda
NPI 1629607635
$3,390.64
in general payments reported to CMS, 2019-2025
24 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,799 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.66 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.27 | 2024-2025 | |
| Dermavant Sciences, INC. | $538.64 | 2024 | Vtama |
| Incyte Corporation | $307.83 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $274.25 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $203.40 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $195.22 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $191.45 | 2025 | Dupixent, Libtayo |
| Janssen Scientific Affairs, LLC | $145.57 | 2025 | Tremfya |
| Amgen INC. | $139.48 | 2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $138.32 | 2024 | Sotyktu |
| Pfizer INC. | $130.77 | 2024-2025 | |
| Ucb, INC. | $87.20 | 2024-2025 | Bimzelx |
| Organon LLC | $70.23 | 2025 | Vtama |
| Ge Healthcare | $64.62 | 2025 | |
| Novartis Pharmaceuticals Corporation | $57.95 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $52.73 | 2025 | |
| Lilly USA, LLC | $45.33 | 2024-2025 | Olumiant, Ebglyss, Taltz |
| Surgenex LLC | $40.52 | 2025 | Pellograft, Ardeograft, Surgraft |
| Almirall LLC | $36.19 | 2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.90 | 2024 | Jublia, Duobrii, Siliq |
| Botanix Sb INC | $29.16 | 2025 | Sofdra |
| Progenics Pharmaceuticals, INC. | $21.00 | 2025 | |
| Genzyme Corporation | $18.92 | 2025 | |
| Galderma Laboratories, L.P. | $14.69 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katerina Warda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.